Lantheus Holdings, Inc. (LNTH) 10-Year Financial Performance & Capital Metrics

LNTH • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryDiagnostic & Imaging Agents

AboutLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.Show more

Revenue $1.53B +18.3%
EBITDA $522M +22.8%
Net Income $312M -4.4%
EPS (Diluted) 4.36 -6.2%
Gross Margin 64.43% +17.7%
EBITDA Margin 34% +3.8%
Operating Margin 29.79% +5.9%
Net Margin 20.37% -19.2%
ROE 32.82% -36.5%
ROIC 45.28% +10.5%
Debt/Equity 0.57 -24.7%
Interest Coverage 23.23 +27.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 30.2%
✓Strong 5Y profit CAGR of 58.1%
✓FCF machine: 32.1% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 34.6%

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y17.66%

5Y34.59%

3Y53.37%

TTM1.95%

Profit (Net Income) CAGR

10Y-

5Y58.06%

3Y-

TTM-60.79%

EPS CAGR

10Y-

5Y40.73%

3Y-

TTM-60.4%

ROCE

10Y Avg15.15%

5Y Avg10.53%

3Y Avg20.4%

Latest28.53%

Peer Comparison

Diagnostic & Imaging Agents

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LNTHLantheus Holdings, Inc.	4.34B	65.42	15.00	18.32%	10.99%	14.98%	11.37%	0.57

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	293.46M	301.85M	331.38M	343.37M	347.34M	339.41M	425.21M	935.06M	1.3B	1.53B
Revenue Growth %	-0.03%	0.03%	0.1%	0.04%	0.01%	-0.02%	0.25%	1.2%	0.39%	0.18%
Cost of Goods Sold+	157.94M	164.07M	169.24M	168.49M	172.53M	200.65M	237.51M	353.36M	586.89M	545.62M
COGS % of Revenue	0.54%	0.54%	0.51%	0.49%	0.5%	0.59%	0.56%	0.38%	0.45%	0.36%
Gross Profit+	135.52M	137.78M	162.13M	174.88M	174.81M	138.76M	187.69M	581.7M	709.54M	988.29M
Gross Margin %	0.46%	0.46%	0.49%	0.51%	0.5%	0.41%	0.44%	0.62%	0.55%	0.64%
Gross Profit Growth %	0.08%	0.02%	0.18%	0.08%	-0%	-0.21%	0.35%	2.1%	0.22%	0.39%
Operating Expenses+	92.99M	87.58M	110.28M	110.4M	123.15M	142.96M	248.52M	545.51M	344.9M	531.31M
OpEx % of Revenue	0.32%	0.29%	0.33%	0.32%	0.35%	0.42%	0.58%	0.58%	0.27%	0.35%
Selling, General & Admin	78.63M	75.37M	92.16M	93.33M	103.13M	110.17M	218.82M	233.83M	267.19M	371.63M
SG&A % of Revenue	0.27%	0.25%	0.28%	0.27%	0.3%	0.32%	0.51%	0.25%	0.21%	0.24%
Research & Development	14.36M	12.2M	18.13M	17.07M	20.02M	32.79M	44.97M	311.68M	77.71M	168.1M
R&D % of Revenue	0.05%	0.04%	0.05%	0.05%	0.06%	0.1%	0.11%	0.33%	0.06%	0.11%
Other Operating Expenses	-89K	220K	0	0	0	0	-15.26M	0	0	-8.41M
Operating Income+	42.53M	56.59M	51.85M	64.49M	51.66M	-4.2M	-60.83M	36.2M	364.64M	456.98M
Operating Margin %	0.14%	0.19%	0.16%	0.19%	0.15%	-0.01%	-0.14%	0.04%	0.28%	0.3%
Operating Income Growth %	0.08%	0.33%	-0.08%	0.24%	-0.2%	-1.08%	-13.49%	1.6%	9.07%	0.25%
EBITDA+	62.18M	74.85M	71M	78.35M	65.04M	20.49M	-18.54M	84.12M	424.69M	521.6M
EBITDA Margin %	0.21%	0.25%	0.21%	0.23%	0.19%	0.06%	-0.04%	0.09%	0.33%	0.34%
EBITDA Growth %	0.08%	0.2%	-0.05%	0.1%	-0.17%	-0.68%	-1.9%	5.54%	4.05%	0.23%
D&A (Non-Cash Add-back)	19.65M	18.26M	19.14M	13.86M	13.38M	24.69M	42.29M	47.93M	60.04M	64.62M
EBIT	26.94M	54.91M	58.05M	66.95M	42.24M	-2M	-67.29M	33.9M	430.96M	450.65M
Net Interest Income+	-38.72M	-26.62M	-18.39M	-17.24M	-12.93M	-9.24M	-7.71M	-4.57M	-381K	17.17M
Interest Income	0	0	18K	167K	686K	238K	45K	2.61M	19.64M	36.84M
Interest Expense	38.72M	26.62M	18.41M	17.41M	13.62M	9.48M	7.75M	7.18M	20.02M	19.67M
Other Income/Expense	-54.31M	-28.29M	-12.21M	-14.94M	-23.03M	-7.28M	-14.21M	-9.48M	46.3M	-26M
Pretax Income+	-11.78M	28.29M	39.64M	49.55M	28.63M	-11.48M	-75.04M	26.72M	410.94M	430.98M
Pretax Margin %	-0.04%	0.09%	0.12%	0.14%	0.08%	-0.03%	-0.18%	0.03%	0.32%	0.28%
Income Tax+	2.97M	1.53M	-83.75M	9.03M	-3.04M	1.99M	-3.76M	-1.35M	84.28M	118.53M
Effective Tax Rate %	1.25%	0.95%	3.11%	0.82%	1.11%	1.17%	0.95%	1.05%	0.79%	0.72%
Net Income+	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Net Margin %	-0.05%	0.09%	0.37%	0.12%	0.09%	-0.04%	-0.17%	0.03%	0.25%	0.2%
Net Income Growth %	-3.14%	2.81%	3.61%	-0.67%	-0.22%	-1.43%	-4.29%	1.39%	10.64%	-0.04%
Net Income (Continuing)	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.60	0.82	3.17	1.03	0.79	-0.25	-1.06	0.40	4.65	4.36
EPS Growth %	-2%	2.37%	2.87%	-0.68%	-0.23%	-1.32%	-3.24%	1.38%	10.63%	-0.06%
EPS (Basic)	-0.60	0.84	3.31	1.06	0.81	-0.25	-1.06	0.41	4.79	4.52
Diluted Shares Outstanding	24.44M	32.66M	38.89M	39.5M	40.11M	54.13M	67.49M	70.67M	70.24M	71.65M
Basic Shares Outstanding	24.44M	32.04M	37.28M	38.23M	38.99M	54.13M	67.49M	68.49M	68.27M	69.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	90.1M	110.82M	147.85M	195.41M	172.91M	184.22M	235.79M	677.62M	1.09B	1.33B
Cash & Short-Term Investments	28.6M	51.18M	76.29M	113.4M	92.92M	79.61M	98.51M	415.65M	713.66M	912.81M
Cash Only	28.6M	51.18M	76.29M	113.4M	92.92M	79.61M	98.51M	415.65M	713.66M	912.81M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	37.29M	36.82M	40.26M	43.75M	43.53M	54M	89.34M	213.4M	284.29M	321.26M
Days Sales Outstanding	46.38	44.52	44.34	46.51	45.74	58.07	76.69	83.3	80.04	76.44
Inventory	15.62M	17.64M	26.08M	33.02M	29.18M	35.74M	35.13M	35.48M	64.03M	68.03M
Days Inventory Outstanding	36.1	39.24	56.25	71.53	61.73	65.02	53.98	36.64	39.82	45.51
Other Current Assets	8.59M	5.18M	5.22M	5.24M	7.28M	5.69M	2.71M	205K	7.41M	9.13M
Total Non-Current Assets+	152.28M	145.08M	236.01M	244.42M	233.01M	685.6M	627.99M	643.64M	565.33M	653.71M
Property, Plant & Equipment	86.52M	94.19M	93M	107.89M	116.5M	138.61M	125.56M	141.2M	192.02M	212.88M
Fixed Asset Turnover	3.39x	3.20x	3.56x	3.18x	2.98x	2.45x	3.39x	6.62x	6.75x	7.21x
Goodwill	15.71M	15.71M	15.71M	15.71M	15.71M	58.63M	61.19M	61.19M	61.19M	61.19M
Intangible Assets	29.63M	15.12M	11.8M	9.13M	7.34M	376.01M	348.51M	315.29M	151.99M	161.76M
Long-Term Investments	74K	0	0	0	0	0	0	0	0	39.49M
Other Non-Current Assets	20.41M	20.06M	28.49M	30.23M	21.63M	42.19M	29.97M	15.32M	9.94M	8.15M
Total Assets+	242.38M	255.9M	383.86M	439.83M	405.92M	869.82M	863.78M	1.32B	1.65B	1.98B
Asset Turnover	1.21x	1.18x	0.86x	0.78x	0.86x	0.39x	0.49x	0.71x	0.79x	0.77x
Asset Growth %	-0.03%	0.06%	0.5%	0.15%	-0.08%	1.14%	-0.01%	0.53%	0.25%	0.2%
Total Current Liabilities+	35.72M	43.84M	46.75M	52.76M	66.11M	80.5M	90.5M	247.7M	187.35M	240.53M
Accounts Payable	11.66M	18.94M	17.46M	17.95M	18.61M	16.28M	20.79M	20.56M	41.19M	34.56M
Days Payables Outstanding	26.94	42.13	37.66	38.9	39.37	29.62	31.94	21.24	25.62	23.12
Short-Term Debt	3.65M	3.65M	2.75M	2.75M	10.14M	20.7M	11.64M	354K	823K	974K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	8.39M	8.94M	12.07M	16.09M	17.05M	25.59M	28.08M	155.65M	48.24M	60.25M
Current Ratio	2.52x	2.53x	3.16x	3.70x	2.62x	2.29x	2.61x	2.74x	5.80x	5.52x
Quick Ratio	2.09x	2.13x	2.60x	3.08x	2.17x	1.84x	2.22x	2.59x	5.45x	5.23x
Cash Conversion Cycle	55.55	41.63	62.93	79.14	68.11	93.47	98.73	98.7	94.25	98.83
Total Non-Current Liabilities+	391.95M	318.57M	313.82M	316.07M	225.21M	275.11M	308.85M	626.41M	647.91M	651.8M
Long-Term Debt	349.86M	274.46M	265.39M	263.71M	183.93M	197.7M	163.12M	557.71M	561.67M	565.28M
Capital Lease Obligations	0	0	0	0	186K	17.5M	16.55M	25.44M	54.45M	53.19M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	42.09M	44.12M	48.42M	52.37M	41.09M	59.91M	129.18M	43.26M	31.78M	33.34M
Total Liabilities	427.67M	362.41M	360.57M	368.83M	291.32M	355.62M	399.35M	874.11M	835.26M	892.33M
Total Debt+	353.51M	278.11M	268.14M	266.46M	194.4M	235.9M	191.31M	583.51M	616.95M	619.44M
Net Debt	324.91M	226.93M	191.85M	153.06M	101.48M	156.29M	92.8M	167.86M	-96.71M	-293.38M
Debt / Equity	-	-	11.51x	3.75x	1.70x	0.46x	0.41x	1.30x	0.76x	0.57x
Debt / EBITDA	5.69x	3.72x	3.78x	3.40x	2.99x	11.51x	-	6.94x	1.45x	1.19x
Net Debt / EBITDA	5.23x	3.03x	2.70x	1.95x	1.56x	7.63x	-	2.00x	-0.23x	-0.56x
Interest Coverage	1.10x	2.13x	2.82x	3.71x	3.79x	-0.44x	-7.85x	5.04x	18.21x	23.23x
Total Equity+	-185.29M	-106.52M	23.29M	71M	114.6M	514.21M	464.44M	447.15M	815.89M	1.09B
Equity Growth %	0.23%	0.43%	1.22%	2.05%	0.61%	3.49%	-0.1%	-0.04%	0.82%	0.33%
Book Value per Share	-7.58	-3.26	0.60	1.80	2.86	9.50	6.88	6.33	11.62	15.18
Total Shareholders' Equity	-185.29M	-106.52M	23.29M	71M	114.6M	514.21M	464.44M	447.15M	815.89M	1.09B
Common Stock	303K	367K	378K	385K	393K	669K	677K	689K	699K	709K
Retained Earnings	-359.16M	-332.4M	-209.01M	-168.14M	-136.47M	-149.95M	-221.22M	-193.16M	133.5M	445.94M
Treasury Stock	0	0	0	0	0	0	0	-75M	-75M	-175M
Accumulated OCI	-1.99M	-947K	-1.03M	-1.11M	-960K	-2.05M	-485K	-1.26M	-1.04M	-1.61M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.76M	49.64M	54.78M	61.19M	80.38M	16.4M	53.92M	281.78M	305.26M	544.75M
Operating CF Margin %	0.07%	0.16%	0.17%	0.18%	0.23%	0.05%	0.13%	0.3%	0.24%	0.36%
Operating CF Growth %	0.88%	1.28%	0.1%	0.12%	0.31%	-0.8%	2.29%	4.23%	0.08%	0.78%
Net Income	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Depreciation & Amortization	19.65M	18.26M	19.23M	13.93M	13.38M	24.69M	42.29M	47.93M	60.04M	64.62M
Stock-Based Compensation	2M	2.52M	5.93M	8.72M	12.49M	14.07M	15.93M	29.26M	50.51M	76.39M
Deferred Taxes	868K	365K	-92.57M	6.13M	7.2M	-724K	3.65M	-50.94M	-55.63M	-24.79M
Other Non-Cash Items	22.22M	-362K	7.12M	5.87M	6.59M	14.19M	78.48M	302.53M	94.88M	114.04M
Working Capital Changes	-8.23M	2.09M	-8.32M	-13.97M	9.05M	-22.36M	-15.15M	-75.06M	-171.2M	2.05M
Change in Receivables	-14K	-1.06M	-3.41M	-3.98M	156K	-7.46M	-33.1M	-128.46M	-68.64M	-37.69M
Change in Inventory	-2.61M	-3.63M	-9.62M	-8.69M	1.99M	-8.46M	-3.55M	-7.51M	-36.22M	-2.67M
Change in Payables	-1.68M	5.7M	604K	-2.89M	3.23M	-4.22M	5.42M	301K	17.19M	-8.8M
Cash from Investing+	-13.15M	3.28M	-16.31M	-19.13M	-22.06M	-4.91M	3.68M	-276.55M	5.94M	-226.01M
Capital Expenditures	-13.15M	-7.4M	-17.54M	-20.13M	-22.06M	-12.47M	-12.14M	-18.35M	-46.55M	-79.63M
CapEx % of Revenue	0.04%	0.02%	0.05%	0.06%	0.06%	0.04%	0.03%	0.02%	0.04%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	10.68M	1.23M	1M	0	-10M	15.82M	-258.2M	52.49M	17.77M
Cash from Financing+	999K	-30.22M	-13.45M	-4.67M	-78.88M	-21.86M	-39.33M	311.69M	-13.06M	-118.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.02M	-2.39M	320K	-2.23M	-1.28M	-7.05M	3.25M	2.95M	-14.28M	-21.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	8.61M	42.24M	37.23M	41.06M	58.32M	3.92M	41.78M	263.43M	258.7M	493.13M
FCF Margin %	0.03%	0.14%	0.11%	0.12%	0.17%	0.01%	0.1%	0.28%	0.2%	0.32%
FCF Growth %	1.49%	3.91%	-0.12%	0.1%	0.42%	-0.93%	9.65%	5.31%	-0.02%	0.91%
FCF per Share	0.35	1.29	0.96	1.04	1.45	0.07	0.62	3.73	3.68	6.88
FCF Conversion (FCF/Net Income)	-1.48x	1.85x	0.44x	1.51x	2.54x	-1.22x	-0.76x	10.04x	0.93x	1.74x
Interest Paid	40.79M	24.44M	16.65M	15.87M	12.25M	9.37M	6.28M	5.06M	15.39M	15.09M
Taxes Paid	174K	265K	106K	90K	12.25M	340K	215K	54.05M	151.58M	153.81M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	529.75%	85.94%	34.12%	-4.29%	-14.57%	6.16%	51.73%	32.82%
Return on Invested Capital (ROIC)	22.16%	32.64%	23.18%	22.02%	17.61%	-0.71%	-7.43%	4.63%	41%	45.28%
Gross Margin	46.18%	45.64%	48.93%	50.93%	50.33%	40.88%	44.14%	62.21%	54.73%	64.43%
Net Margin	-5.02%	8.87%	37.23%	11.8%	9.12%	-3.97%	-16.76%	3%	25.2%	20.37%
Debt / Equity	-	-	11.51x	3.75x	1.70x	0.46x	0.41x	1.30x	0.76x	0.57x
Interest Coverage	1.10x	2.13x	2.82x	3.71x	3.79x	-0.44x	-7.85x	5.04x	18.21x	23.23x
FCF Conversion	-1.48x	1.85x	0.44x	1.51x	2.54x	-1.22x	-0.76x	10.04x	0.93x	1.74x
Revenue Growth	-2.7%	2.86%	9.78%	3.62%	1.15%	-2.28%	25.28%	119.91%	38.65%	18.32%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	1.26B	1.52B
Product Growth	-	-	-	-	-	-	-	-	-	20.72%
Radiopharmaceutical Oncology	-	-	-	-	-	-	48.89M	531.51M	854.43M	1.06B
Radiopharmaceutical Oncology Growth	-	-	-	-	-	-	-	987.22%	60.76%	23.85%
PYLARIFY	-	-	-	-	-	-	43.41M	527.4M	851.3M	1.06B
PYLARIFY Growth	-	-	-	-	-	-	-	1114.83%	61.41%	24.26%
Total Precision Diagnostics	-	-	-	-	-	-	351.02M	356.68M	390.12M	437.51M
Total Precision Diagnostics Growth	-	-	-	-	-	-	-	1.61%	9.37%	12.15%
DEFINITY	-	131.61M	-	183.07M	-	-	232.76M	244.99M	279.77M	317.79M
DEFINITY Growth	-	-	-	-	-	-	-	5.26%	14.19%	13.59%
Techne Lite	72.56M	99.22M	-	98.86M	-	-	91.29M	88.86M	87.37M	95.49M
Techne Lite Growth	-	36.73%	-	-	-	-	-	-2.66%	-1.68%	9.29%
Strategic Partnerships And Other	-	-	-	-	-	-	25.3M	46.87M	51.88M	38.18M
Strategic Partnerships And Other Growth	-	-	-	-	-	-	-	85.29%	10.68%	-26.40%
Other Precision Diagnostics	-	-	-	-	-	-	26.97M	22.82M	22.98M	24.23M
Other Precision Diagnostics Growth	-	-	-	-	-	-	-	-15.38%	0.68%	5.44%
License and Royalty Revenues	-	-	-	-	-	-	24.85M	48.02M	33.36M	9.13M
License and Royalty Revenues Growth	-	-	-	-	-	-	-	93.24%	-30.53%	-72.64%
Other Radiopharmaceutical Oncology	-	-	-	-	-	-	5.47M	4.1M	3.13M	384K
Other Radiopharmaceutical Oncology Growth	-	-	-	-	-	-	-	-25.05%	-23.70%	-87.73%
Product Revenue, Net	-	-	-	-	-	-	400.36M	887.04M	-	-
Product Revenue, Net Growth	-	-	-	-	-	-	-	121.56%	-	-
US	-	-	290M	-	303.99M	294.8M	-	-	-	-
US Growth	-	-	-	-	-	-3.02%	-	-	-	-
International	-	-	41.38M	-	43.35M	44.61M	-	-	-	-
International Growth	-	-	-	-	-	2.92%	-	-	-	-
Other Products	-	-	-	61.44M	-	-	-	-	-	-
Other Products Growth	-	-	-	-	-	-	-	-	-	-
Xenon	48.9M	29.09M	-	-	-	-	-	-	-	-
Xenon Growth	-	-40.52%	-	-	-	-	-	-	-	-
Definity	111.86M	-	-	-	-	-	-	-	-	-
Definity Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
US	-	-	-	-	303.99M	294.8M	-	-	-	-
US Growth	-	-	-	-	-	-3.02%	-	-	-	-
Worldwide	-	-	-	-	347.34M	44.61M	-	-	-	-
Worldwide Growth	-	-	-	-	-	-87.16%	-	-	-	-
UNITED STATES	235.82M	257.42M	290M	288.58M	-	-	-	-	-	-
UNITED STATES Growth	-	9.16%	12.66%	-0.49%	-	-	-	-	-	-
All Other	29.3M	25.52M	22.61M	54.79M	-	-	-	-	-	-
All Other Growth	-	-12.91%	-11.40%	142.39%	-	-	-	-	-	-
CANADA	28.34M	18.92M	18.77M	-	-	-	-	-	-	-
CANADA Growth	-	-33.25%	-0.78%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Lantheus Holdings, Inc. (LNTH) has a price-to-earnings (P/E) ratio of 15.0x. This is roughly in line with market averages.

Growth & Financials

Lantheus Holdings, Inc. (LNTH) reported $1.53B in revenue for fiscal year 2024. This represents a 430% increase from $288.1M in 2012.

Lantheus Holdings, Inc. (LNTH) grew revenue by 18.3% over the past year. This is strong growth.

Yes, Lantheus Holdings, Inc. (LNTH) is profitable, generating $167.7M in net income for fiscal year 2024 (20.4% net margin).

Dividend & Returns

Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 32.8%. This is excellent, indicating efficient use of shareholder capital.

Lantheus Holdings, Inc. (LNTH) generated $406.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Lantheus Holdings, Inc. (LNTH) 10-Year Financial Performance & Capital Metrics

LNTH • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryDiagnostic & Imaging Agents

Revenue $1.53B +18.3%
EBITDA $522M +22.8%
Net Income $312M -4.4%
EPS (Diluted) 4.36 -6.2%
Gross Margin 64.43% +17.7%
EBITDA Margin 34% +3.8%
Operating Margin 29.79% +5.9%
Net Margin 20.37% -19.2%
ROE 32.82% -36.5%
ROIC 45.28% +10.5%
Debt/Equity 0.57 -24.7%
Interest Coverage 23.23 +27.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 30.2%
✓Strong 5Y profit CAGR of 58.1%
✓FCF machine: 32.1% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 34.6%

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y17.66%

5Y34.59%

3Y53.37%

TTM1.95%

Profit (Net Income) CAGR

10Y-

5Y58.06%

3Y-

TTM-60.79%

EPS CAGR

10Y-

5Y40.73%

3Y-

TTM-60.4%

ROCE

10Y Avg15.15%

5Y Avg10.53%

3Y Avg20.4%

Latest28.53%

Peer Comparison

Diagnostic & Imaging Agents

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LNTHLantheus Holdings, Inc.	4.34B	65.42	15.00	18.32%	10.99%	14.98%	11.37%	0.57

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	293.46M	301.85M	331.38M	343.37M	347.34M	339.41M	425.21M	935.06M	1.3B	1.53B
Revenue Growth %	-0.03%	0.03%	0.1%	0.04%	0.01%	-0.02%	0.25%	1.2%	0.39%	0.18%
Cost of Goods Sold+	157.94M	164.07M	169.24M	168.49M	172.53M	200.65M	237.51M	353.36M	586.89M	545.62M
COGS % of Revenue	0.54%	0.54%	0.51%	0.49%	0.5%	0.59%	0.56%	0.38%	0.45%	0.36%
Gross Profit+	135.52M	137.78M	162.13M	174.88M	174.81M	138.76M	187.69M	581.7M	709.54M	988.29M
Gross Margin %	0.46%	0.46%	0.49%	0.51%	0.5%	0.41%	0.44%	0.62%	0.55%	0.64%
Gross Profit Growth %	0.08%	0.02%	0.18%	0.08%	-0%	-0.21%	0.35%	2.1%	0.22%	0.39%
Operating Expenses+	92.99M	87.58M	110.28M	110.4M	123.15M	142.96M	248.52M	545.51M	344.9M	531.31M
OpEx % of Revenue	0.32%	0.29%	0.33%	0.32%	0.35%	0.42%	0.58%	0.58%	0.27%	0.35%
Selling, General & Admin	78.63M	75.37M	92.16M	93.33M	103.13M	110.17M	218.82M	233.83M	267.19M	371.63M
SG&A % of Revenue	0.27%	0.25%	0.28%	0.27%	0.3%	0.32%	0.51%	0.25%	0.21%	0.24%
Research & Development	14.36M	12.2M	18.13M	17.07M	20.02M	32.79M	44.97M	311.68M	77.71M	168.1M
R&D % of Revenue	0.05%	0.04%	0.05%	0.05%	0.06%	0.1%	0.11%	0.33%	0.06%	0.11%
Other Operating Expenses	-89K	220K	0	0	0	0	-15.26M	0	0	-8.41M
Operating Income+	42.53M	56.59M	51.85M	64.49M	51.66M	-4.2M	-60.83M	36.2M	364.64M	456.98M
Operating Margin %	0.14%	0.19%	0.16%	0.19%	0.15%	-0.01%	-0.14%	0.04%	0.28%	0.3%
Operating Income Growth %	0.08%	0.33%	-0.08%	0.24%	-0.2%	-1.08%	-13.49%	1.6%	9.07%	0.25%
EBITDA+	62.18M	74.85M	71M	78.35M	65.04M	20.49M	-18.54M	84.12M	424.69M	521.6M
EBITDA Margin %	0.21%	0.25%	0.21%	0.23%	0.19%	0.06%	-0.04%	0.09%	0.33%	0.34%
EBITDA Growth %	0.08%	0.2%	-0.05%	0.1%	-0.17%	-0.68%	-1.9%	5.54%	4.05%	0.23%
D&A (Non-Cash Add-back)	19.65M	18.26M	19.14M	13.86M	13.38M	24.69M	42.29M	47.93M	60.04M	64.62M
EBIT	26.94M	54.91M	58.05M	66.95M	42.24M	-2M	-67.29M	33.9M	430.96M	450.65M
Net Interest Income+	-38.72M	-26.62M	-18.39M	-17.24M	-12.93M	-9.24M	-7.71M	-4.57M	-381K	17.17M
Interest Income	0	0	18K	167K	686K	238K	45K	2.61M	19.64M	36.84M
Interest Expense	38.72M	26.62M	18.41M	17.41M	13.62M	9.48M	7.75M	7.18M	20.02M	19.67M
Other Income/Expense	-54.31M	-28.29M	-12.21M	-14.94M	-23.03M	-7.28M	-14.21M	-9.48M	46.3M	-26M
Pretax Income+	-11.78M	28.29M	39.64M	49.55M	28.63M	-11.48M	-75.04M	26.72M	410.94M	430.98M
Pretax Margin %	-0.04%	0.09%	0.12%	0.14%	0.08%	-0.03%	-0.18%	0.03%	0.32%	0.28%
Income Tax+	2.97M	1.53M	-83.75M	9.03M	-3.04M	1.99M	-3.76M	-1.35M	84.28M	118.53M
Effective Tax Rate %	1.25%	0.95%	3.11%	0.82%	1.11%	1.17%	0.95%	1.05%	0.79%	0.72%
Net Income+	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Net Margin %	-0.05%	0.09%	0.37%	0.12%	0.09%	-0.04%	-0.17%	0.03%	0.25%	0.2%
Net Income Growth %	-3.14%	2.81%	3.61%	-0.67%	-0.22%	-1.43%	-4.29%	1.39%	10.64%	-0.04%
Net Income (Continuing)	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.60	0.82	3.17	1.03	0.79	-0.25	-1.06	0.40	4.65	4.36
EPS Growth %	-2%	2.37%	2.87%	-0.68%	-0.23%	-1.32%	-3.24%	1.38%	10.63%	-0.06%
EPS (Basic)	-0.60	0.84	3.31	1.06	0.81	-0.25	-1.06	0.41	4.79	4.52
Diluted Shares Outstanding	24.44M	32.66M	38.89M	39.5M	40.11M	54.13M	67.49M	70.67M	70.24M	71.65M
Basic Shares Outstanding	24.44M	32.04M	37.28M	38.23M	38.99M	54.13M	67.49M	68.49M	68.27M	69.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	90.1M	110.82M	147.85M	195.41M	172.91M	184.22M	235.79M	677.62M	1.09B	1.33B
Cash & Short-Term Investments	28.6M	51.18M	76.29M	113.4M	92.92M	79.61M	98.51M	415.65M	713.66M	912.81M
Cash Only	28.6M	51.18M	76.29M	113.4M	92.92M	79.61M	98.51M	415.65M	713.66M	912.81M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	37.29M	36.82M	40.26M	43.75M	43.53M	54M	89.34M	213.4M	284.29M	321.26M
Days Sales Outstanding	46.38	44.52	44.34	46.51	45.74	58.07	76.69	83.3	80.04	76.44
Inventory	15.62M	17.64M	26.08M	33.02M	29.18M	35.74M	35.13M	35.48M	64.03M	68.03M
Days Inventory Outstanding	36.1	39.24	56.25	71.53	61.73	65.02	53.98	36.64	39.82	45.51
Other Current Assets	8.59M	5.18M	5.22M	5.24M	7.28M	5.69M	2.71M	205K	7.41M	9.13M
Total Non-Current Assets+	152.28M	145.08M	236.01M	244.42M	233.01M	685.6M	627.99M	643.64M	565.33M	653.71M
Property, Plant & Equipment	86.52M	94.19M	93M	107.89M	116.5M	138.61M	125.56M	141.2M	192.02M	212.88M
Fixed Asset Turnover	3.39x	3.20x	3.56x	3.18x	2.98x	2.45x	3.39x	6.62x	6.75x	7.21x
Goodwill	15.71M	15.71M	15.71M	15.71M	15.71M	58.63M	61.19M	61.19M	61.19M	61.19M
Intangible Assets	29.63M	15.12M	11.8M	9.13M	7.34M	376.01M	348.51M	315.29M	151.99M	161.76M
Long-Term Investments	74K	0	0	0	0	0	0	0	0	39.49M
Other Non-Current Assets	20.41M	20.06M	28.49M	30.23M	21.63M	42.19M	29.97M	15.32M	9.94M	8.15M
Total Assets+	242.38M	255.9M	383.86M	439.83M	405.92M	869.82M	863.78M	1.32B	1.65B	1.98B
Asset Turnover	1.21x	1.18x	0.86x	0.78x	0.86x	0.39x	0.49x	0.71x	0.79x	0.77x
Asset Growth %	-0.03%	0.06%	0.5%	0.15%	-0.08%	1.14%	-0.01%	0.53%	0.25%	0.2%
Total Current Liabilities+	35.72M	43.84M	46.75M	52.76M	66.11M	80.5M	90.5M	247.7M	187.35M	240.53M
Accounts Payable	11.66M	18.94M	17.46M	17.95M	18.61M	16.28M	20.79M	20.56M	41.19M	34.56M
Days Payables Outstanding	26.94	42.13	37.66	38.9	39.37	29.62	31.94	21.24	25.62	23.12
Short-Term Debt	3.65M	3.65M	2.75M	2.75M	10.14M	20.7M	11.64M	354K	823K	974K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	8.39M	8.94M	12.07M	16.09M	17.05M	25.59M	28.08M	155.65M	48.24M	60.25M
Current Ratio	2.52x	2.53x	3.16x	3.70x	2.62x	2.29x	2.61x	2.74x	5.80x	5.52x
Quick Ratio	2.09x	2.13x	2.60x	3.08x	2.17x	1.84x	2.22x	2.59x	5.45x	5.23x
Cash Conversion Cycle	55.55	41.63	62.93	79.14	68.11	93.47	98.73	98.7	94.25	98.83
Total Non-Current Liabilities+	391.95M	318.57M	313.82M	316.07M	225.21M	275.11M	308.85M	626.41M	647.91M	651.8M
Long-Term Debt	349.86M	274.46M	265.39M	263.71M	183.93M	197.7M	163.12M	557.71M	561.67M	565.28M
Capital Lease Obligations	0	0	0	0	186K	17.5M	16.55M	25.44M	54.45M	53.19M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	42.09M	44.12M	48.42M	52.37M	41.09M	59.91M	129.18M	43.26M	31.78M	33.34M
Total Liabilities	427.67M	362.41M	360.57M	368.83M	291.32M	355.62M	399.35M	874.11M	835.26M	892.33M
Total Debt+	353.51M	278.11M	268.14M	266.46M	194.4M	235.9M	191.31M	583.51M	616.95M	619.44M
Net Debt	324.91M	226.93M	191.85M	153.06M	101.48M	156.29M	92.8M	167.86M	-96.71M	-293.38M
Debt / Equity	-	-	11.51x	3.75x	1.70x	0.46x	0.41x	1.30x	0.76x	0.57x
Debt / EBITDA	5.69x	3.72x	3.78x	3.40x	2.99x	11.51x	-	6.94x	1.45x	1.19x
Net Debt / EBITDA	5.23x	3.03x	2.70x	1.95x	1.56x	7.63x	-	2.00x	-0.23x	-0.56x
Interest Coverage	1.10x	2.13x	2.82x	3.71x	3.79x	-0.44x	-7.85x	5.04x	18.21x	23.23x
Total Equity+	-185.29M	-106.52M	23.29M	71M	114.6M	514.21M	464.44M	447.15M	815.89M	1.09B
Equity Growth %	0.23%	0.43%	1.22%	2.05%	0.61%	3.49%	-0.1%	-0.04%	0.82%	0.33%
Book Value per Share	-7.58	-3.26	0.60	1.80	2.86	9.50	6.88	6.33	11.62	15.18
Total Shareholders' Equity	-185.29M	-106.52M	23.29M	71M	114.6M	514.21M	464.44M	447.15M	815.89M	1.09B
Common Stock	303K	367K	378K	385K	393K	669K	677K	689K	699K	709K
Retained Earnings	-359.16M	-332.4M	-209.01M	-168.14M	-136.47M	-149.95M	-221.22M	-193.16M	133.5M	445.94M
Treasury Stock	0	0	0	0	0	0	0	-75M	-75M	-175M
Accumulated OCI	-1.99M	-947K	-1.03M	-1.11M	-960K	-2.05M	-485K	-1.26M	-1.04M	-1.61M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.76M	49.64M	54.78M	61.19M	80.38M	16.4M	53.92M	281.78M	305.26M	544.75M
Operating CF Margin %	0.07%	0.16%	0.17%	0.18%	0.23%	0.05%	0.13%	0.3%	0.24%	0.36%
Operating CF Growth %	0.88%	1.28%	0.1%	0.12%	0.31%	-0.8%	2.29%	4.23%	0.08%	0.78%
Net Income	-14.75M	26.76M	123.39M	40.52M	31.67M	-13.47M	-71.28M	28.07M	326.66M	312.44M
Depreciation & Amortization	19.65M	18.26M	19.23M	13.93M	13.38M	24.69M	42.29M	47.93M	60.04M	64.62M
Stock-Based Compensation	2M	2.52M	5.93M	8.72M	12.49M	14.07M	15.93M	29.26M	50.51M	76.39M
Deferred Taxes	868K	365K	-92.57M	6.13M	7.2M	-724K	3.65M	-50.94M	-55.63M	-24.79M
Other Non-Cash Items	22.22M	-362K	7.12M	5.87M	6.59M	14.19M	78.48M	302.53M	94.88M	114.04M
Working Capital Changes	-8.23M	2.09M	-8.32M	-13.97M	9.05M	-22.36M	-15.15M	-75.06M	-171.2M	2.05M
Change in Receivables	-14K	-1.06M	-3.41M	-3.98M	156K	-7.46M	-33.1M	-128.46M	-68.64M	-37.69M
Change in Inventory	-2.61M	-3.63M	-9.62M	-8.69M	1.99M	-8.46M	-3.55M	-7.51M	-36.22M	-2.67M
Change in Payables	-1.68M	5.7M	604K	-2.89M	3.23M	-4.22M	5.42M	301K	17.19M	-8.8M
Cash from Investing+	-13.15M	3.28M	-16.31M	-19.13M	-22.06M	-4.91M	3.68M	-276.55M	5.94M	-226.01M
Capital Expenditures	-13.15M	-7.4M	-17.54M	-20.13M	-22.06M	-12.47M	-12.14M	-18.35M	-46.55M	-79.63M
CapEx % of Revenue	0.04%	0.02%	0.05%	0.06%	0.06%	0.04%	0.03%	0.02%	0.04%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	10.68M	1.23M	1M	0	-10M	15.82M	-258.2M	52.49M	17.77M
Cash from Financing+	999K	-30.22M	-13.45M	-4.67M	-78.88M	-21.86M	-39.33M	311.69M	-13.06M	-118.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.02M	-2.39M	320K	-2.23M	-1.28M	-7.05M	3.25M	2.95M	-14.28M	-21.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	8.61M	42.24M	37.23M	41.06M	58.32M	3.92M	41.78M	263.43M	258.7M	493.13M
FCF Margin %	0.03%	0.14%	0.11%	0.12%	0.17%	0.01%	0.1%	0.28%	0.2%	0.32%
FCF Growth %	1.49%	3.91%	-0.12%	0.1%	0.42%	-0.93%	9.65%	5.31%	-0.02%	0.91%
FCF per Share	0.35	1.29	0.96	1.04	1.45	0.07	0.62	3.73	3.68	6.88
FCF Conversion (FCF/Net Income)	-1.48x	1.85x	0.44x	1.51x	2.54x	-1.22x	-0.76x	10.04x	0.93x	1.74x
Interest Paid	40.79M	24.44M	16.65M	15.87M	12.25M	9.37M	6.28M	5.06M	15.39M	15.09M
Taxes Paid	174K	265K	106K	90K	12.25M	340K	215K	54.05M	151.58M	153.81M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	529.75%	85.94%	34.12%	-4.29%	-14.57%	6.16%	51.73%	32.82%
Return on Invested Capital (ROIC)	22.16%	32.64%	23.18%	22.02%	17.61%	-0.71%	-7.43%	4.63%	41%	45.28%
Gross Margin	46.18%	45.64%	48.93%	50.93%	50.33%	40.88%	44.14%	62.21%	54.73%	64.43%
Net Margin	-5.02%	8.87%	37.23%	11.8%	9.12%	-3.97%	-16.76%	3%	25.2%	20.37%
Debt / Equity	-	-	11.51x	3.75x	1.70x	0.46x	0.41x	1.30x	0.76x	0.57x
Interest Coverage	1.10x	2.13x	2.82x	3.71x	3.79x	-0.44x	-7.85x	5.04x	18.21x	23.23x
FCF Conversion	-1.48x	1.85x	0.44x	1.51x	2.54x	-1.22x	-0.76x	10.04x	0.93x	1.74x
Revenue Growth	-2.7%	2.86%	9.78%	3.62%	1.15%	-2.28%	25.28%	119.91%	38.65%	18.32%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	1.26B	1.52B
Product Growth	-	-	-	-	-	-	-	-	-	20.72%
Radiopharmaceutical Oncology	-	-	-	-	-	-	48.89M	531.51M	854.43M	1.06B
Radiopharmaceutical Oncology Growth	-	-	-	-	-	-	-	987.22%	60.76%	23.85%
PYLARIFY	-	-	-	-	-	-	43.41M	527.4M	851.3M	1.06B
PYLARIFY Growth	-	-	-	-	-	-	-	1114.83%	61.41%	24.26%
Total Precision Diagnostics	-	-	-	-	-	-	351.02M	356.68M	390.12M	437.51M
Total Precision Diagnostics Growth	-	-	-	-	-	-	-	1.61%	9.37%	12.15%
DEFINITY	-	131.61M	-	183.07M	-	-	232.76M	244.99M	279.77M	317.79M
DEFINITY Growth	-	-	-	-	-	-	-	5.26%	14.19%	13.59%
Techne Lite	72.56M	99.22M	-	98.86M	-	-	91.29M	88.86M	87.37M	95.49M
Techne Lite Growth	-	36.73%	-	-	-	-	-	-2.66%	-1.68%	9.29%
Strategic Partnerships And Other	-	-	-	-	-	-	25.3M	46.87M	51.88M	38.18M
Strategic Partnerships And Other Growth	-	-	-	-	-	-	-	85.29%	10.68%	-26.40%
Other Precision Diagnostics	-	-	-	-	-	-	26.97M	22.82M	22.98M	24.23M
Other Precision Diagnostics Growth	-	-	-	-	-	-	-	-15.38%	0.68%	5.44%
License and Royalty Revenues	-	-	-	-	-	-	24.85M	48.02M	33.36M	9.13M
License and Royalty Revenues Growth	-	-	-	-	-	-	-	93.24%	-30.53%	-72.64%
Other Radiopharmaceutical Oncology	-	-	-	-	-	-	5.47M	4.1M	3.13M	384K
Other Radiopharmaceutical Oncology Growth	-	-	-	-	-	-	-	-25.05%	-23.70%	-87.73%
Product Revenue, Net	-	-	-	-	-	-	400.36M	887.04M	-	-
Product Revenue, Net Growth	-	-	-	-	-	-	-	121.56%	-	-
US	-	-	290M	-	303.99M	294.8M	-	-	-	-
US Growth	-	-	-	-	-	-3.02%	-	-	-	-
International	-	-	41.38M	-	43.35M	44.61M	-	-	-	-
International Growth	-	-	-	-	-	2.92%	-	-	-	-
Other Products	-	-	-	61.44M	-	-	-	-	-	-
Other Products Growth	-	-	-	-	-	-	-	-	-	-
Xenon	48.9M	29.09M	-	-	-	-	-	-	-	-
Xenon Growth	-	-40.52%	-	-	-	-	-	-	-	-
Definity	111.86M	-	-	-	-	-	-	-	-	-
Definity Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
US	-	-	-	-	303.99M	294.8M	-	-	-	-
US Growth	-	-	-	-	-	-3.02%	-	-	-	-
Worldwide	-	-	-	-	347.34M	44.61M	-	-	-	-
Worldwide Growth	-	-	-	-	-	-87.16%	-	-	-	-
UNITED STATES	235.82M	257.42M	290M	288.58M	-	-	-	-	-	-
UNITED STATES Growth	-	9.16%	12.66%	-0.49%	-	-	-	-	-	-
All Other	29.3M	25.52M	22.61M	54.79M	-	-	-	-	-	-
All Other Growth	-	-12.91%	-11.40%	142.39%	-	-	-	-	-	-
CANADA	28.34M	18.92M	18.77M	-	-	-	-	-	-	-
CANADA Growth	-	-33.25%	-0.78%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Lantheus Holdings, Inc. (LNTH) has a price-to-earnings (P/E) ratio of 15.0x. This is roughly in line with market averages.

Growth & Financials

Lantheus Holdings, Inc. (LNTH) reported $1.53B in revenue for fiscal year 2024. This represents a 430% increase from $288.1M in 2012.

Lantheus Holdings, Inc. (LNTH) grew revenue by 18.3% over the past year. This is strong growth.

Yes, Lantheus Holdings, Inc. (LNTH) is profitable, generating $167.7M in net income for fiscal year 2024 (20.4% net margin).

Dividend & Returns

Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 32.8%. This is excellent, indicating efficient use of shareholder capital.

Lantheus Holdings, Inc. (LNTH) generated $406.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.